KR880012633A - C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물 - Google Patents

C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물 Download PDF

Info

Publication number
KR880012633A
KR880012633A KR1019880004512A KR880004512A KR880012633A KR 880012633 A KR880012633 A KR 880012633A KR 1019880004512 A KR1019880004512 A KR 1019880004512A KR 880004512 A KR880004512 A KR 880004512A KR 880012633 A KR880012633 A KR 880012633A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
androst
cyclopropylamino
ene
Prior art date
Application number
KR1019880004512A
Other languages
English (en)
Other versions
KR960015037B1 (ko
Inventor
알.앤젤라스트로 마이클
알.블롬 토마스
Original Assignee
게리 디.스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디.스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 게리 디.스트리트
Publication of KR880012633A publication Critical patent/KR880012633A/ko
Application granted granted Critical
Publication of KR960015037B1 publication Critical patent/KR960015037B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

내용 없음

Description

C17내지 C20리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(Ⅰ)의 화합물.
    상기식에서, R은 수소 또는 메틸이고; R1는 수소, C1내지 C4알킬 또는 사이클로프로필이며;
    이다(여기서, Z는 수소, 탄소수 1 내지 10의 알카노일 또는 알카노일 부분이 4개 이하의 탄소원자를 함유하는 사이클로펜탈- 및 벤젤-알카노일이다)
  2. 제 1항에 있어서, 일반식(Ⅰ')의 화합물.
    상기식에서, R은 수소 또는 메틸이고; R1는 수소, C1내지 C4알킬 또는 사이클로프로필이다.
  3. 제 1항에 있어서, 일반식(Ⅰ)의 화합물.
    상기식에서, R은 수소 또는 메틸이고; R1는 수소, C1내지 C4알킬이다.
  4. 제 1항에 있어서, 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올린 화합물.
  5. 제 1항에 있어서, 17β-[N-메틸(사이클로프로필아미노)]안드로스트-5-엔-3β-올린 화합물.
  6. 제 1항에 있어서, 17β-(사이클로프로필아미노)안드로스트-4-엔-3-온인 화합물.
  7. 안드로겐-의존성 질병을 앓고 있는 개개 환자에게 일반식(Ⅰ)의 화합물 유효량을 투여함을 특징으로 하여 안드로겐-의존성 질병을 치료하는 방법.
    상기식에서, R은 수소 또는 메틸이고; R1는 수소, C1내지 C4알킬 또는 사이클로프로필이며;Q는
    이다(여기서, Z는 수소, 탄소수 1 내지 10의 알카노일 또는 알카노일 부분이 4개 이하의 탄소원자를 함유하는 사이클로펜탄-및 벤젠-알카노일이다).
  8. 제 7항에 있어서, 안드로겐-의존성 질병을 앓고 있는 개개 환자에게 일반식(Ⅰ')의 화합물 유효량을 투여함을 특징으로 하여 안드로겐-의존성 질병을 치료하는 방법.
    상기식에서, R은 수소 또는 메틸이고; R'는 수소, C1내지 C4알킬 또는 사이클로프로필이다.
  9. 제 7항에 있어서, 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 유효량을 투여하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880004512A 1987-04-22 1988-04-21 C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물 KR960015037B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22
US041,172 1987-04-22
US041172 1987-04-22

Publications (2)

Publication Number Publication Date
KR880012633A true KR880012633A (ko) 1988-11-28
KR960015037B1 KR960015037B1 (ko) 1996-10-24

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004512A KR960015037B1 (ko) 1987-04-22 1988-04-21 C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물

Country Status (19)

Country Link
EP (1) EP0288053B1 (ko)
JP (1) JP2711672B2 (ko)
KR (1) KR960015037B1 (ko)
CN (1) CN88102176A (ko)
AT (1) ATE67211T1 (ko)
AU (1) AU606677B2 (ko)
CA (1) CA1326234C (ko)
DE (1) DE3864725D1 (ko)
DK (1) DK217588A (ko)
ES (1) ES2038712T3 (ko)
FI (1) FI88397C (ko)
GR (1) GR3002713T3 (ko)
HU (1) HU198511B (ko)
IL (1) IL86139A (ko)
NO (1) NO169346C (ko)
NZ (1) NZ224288A (ko)
PH (1) PH24090A (ko)
PT (1) PT87294B (ko)
ZA (1) ZA882717B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
NZ249911A (en) * 1992-03-31 1996-06-25 British Tech Group 17-(3-pyridyl) substituted steroids and use in pharmaceutical compositions
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
SI1334106T1 (sl) 2000-11-17 2006-10-31 Takeda Pharmaceutical Imidazolni derivati, njihov proizvodni postopek in njihova uporaba
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JO2892B1 (en) 2009-06-26 2015-09-15 نوفارتيس ايه جي CYP inhibitors 17
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (ko) * 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
AU1471988A (en) 1988-10-27
HUT47307A (en) 1989-02-28
NO169346B (no) 1992-03-02
JPS63284195A (ja) 1988-11-21
KR960015037B1 (ko) 1996-10-24
CA1326234C (en) 1994-01-18
EP0288053B1 (en) 1991-09-11
ZA882717B (en) 1988-10-17
FI88397C (fi) 1993-05-10
JP2711672B2 (ja) 1998-02-10
NZ224288A (en) 1989-12-21
DE3864725D1 (de) 1991-10-17
FI881877A0 (fi) 1988-04-21
FI881877A (fi) 1988-10-23
AU606677B2 (en) 1991-02-14
NO881746D0 (no) 1988-04-21
ATE67211T1 (de) 1991-09-15
NO881746L (no) 1988-10-24
PT87294A (pt) 1988-05-01
HU198511B (en) 1989-10-30
DK217588D0 (da) 1988-04-21
DK217588A (da) 1988-10-23
PH24090A (en) 1990-03-05
ES2038712T3 (es) 1993-08-01
GR3002713T3 (en) 1993-01-25
NO169346C (no) 1992-06-10
CN88102176A (zh) 1988-11-23
IL86139A (en) 1993-02-21
PT87294B (pt) 1992-08-31
IL86139A0 (en) 1988-11-15
EP0288053A1 (en) 1988-10-26
FI88397B (fi) 1993-01-29

Similar Documents

Publication Publication Date Title
KR880012633A (ko) C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물
KR910004650A (ko) C_17-20 리아제 억제제로 유용한 4-치환 17β-(시클로프로필옥시) 안드로스트-5-엔-3β-올 및 그의 관련 화합물
GR851881B (ko)
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
KR910004649A (ko) C_17-20 리아제 억제제로 유용한 4-치환 17β-(시클로프로필아미노) 안드로스트-5-엔-3β-올 및 그의 관련 화합물
KR880012634A (ko) C_17-20리아제 억제제로서 유용한 17β-(사이클로프로필옥시)안드로스트-5-엔-3β-올 및 관련 화합물
PT88648A (pt) Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same
GR3004855T3 (ko)
ES8404694A1 (es) Procedimiento de preparacion de nuevos derivos de amino-14 esteroides
KR900006360A (ko) 3β, 17β- 하이드록시-치환된 스테로이드 및 관련 스테로이드성 화합물
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR910015301A (ko) 수면 무호흡증의 치료방법
HUT38346A (en) Process for producing azabicyclo-heptane derivatives pharmaceutical compositions containing them
ATE73136T1 (de) Verfahren zur herstellung von 6alpha, 9alphadifluor-11beta, 17alpha-dihydroxy-16alpha-methyl4-pregnen-3,20-dion und dessen derivate.
GR77740B (ko)
KR910011888A (ko) 아로마타제 및 19- 하이드록실라제 억제제로서의 2, 19-메틸렌옥시 및 2,19- 메틸렌티오 브릿지된 스테로이드
KR910000160A (ko) 17-시클로프로필아미노안드로스텐 유도체를 함유한 알도스테론 억제제
KR830010070A (ko) 새로운 페닐 피페리딘의 제조방법
KR890002059A (ko) 비스-3급-부틸아미노-치환된 1,3,5- 트리아진 유도체 및 이의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021017

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee